PriceTargets.com logo

Nuwellis - CHFS Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.37 As of 04/15/2024 01:00 AM ET
+0 (0.00%)
Get New Nuwellis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CHFS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CHFS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Nuwellis in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.37.

This chart shows the closing price for CHFS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Nuwellis. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/24/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/19/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/16/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/12/2020Maxim GroupReiterated RatingBuyLow
10/21/2020Maxim GroupLower Target$45.00 ➝ $20.00Low
6/5/2020Maxim GroupInitiated CoverageBuy$1.50High
(Data available from 4/16/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/17/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/17/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/16/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Nuwellis logo
Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.
Read More

Today's Range

Now: $0.37
Low: $0.35
High: $0.39

50 Day Range

MA: $4.79
Low: $3.53
High: $6.02

52 Week Range

Now: $0.37
Low: $4.86
High: $37.50

Volume

54,015 shs

Average Volume

467,323 shs

Market Capitalization

$2.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.55

Frequently Asked Questions

What sell-side analysts currently cover shares of Nuwellis?

The following Wall Street sell-side analysts have issued reports on Nuwellis in the last year:
View the latest analyst ratings for CHFS.

What is the current price target for Nuwellis?

0 Wall Street analysts have set twelve-month price targets for Nuwellis in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Nuwellis in the next year.
View the latest price targets for CHFS.

What is the current consensus analyst rating for Nuwellis?

Nuwellis currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CHFS.

What other companies compete with Nuwellis?

Other companies that are similar to Nuwellis include Nuwellis, Tivic Health Systems, ENDRA Life Sciences, Helius Medical Technologies and Gamida Cell. Learn More about companies similar to Nuwellis.

How do I contact Nuwellis' investor relations team?

Nuwellis' physical mailing address is 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN, 55344. The company's listed phone number is (952) 345-4200 and its investor relations email address is [email protected]. The official website for Nuwellis is www.chf-solutions.com. Learn More about contacing Nuwellis investor relations.